In diseases such as IBD and atherosclerosis, writers can modulate the expression of solute carrier family 37 member 2 (SLC37A2), macrophage scavenger receptor 1 (MSR1), and scavenger receptor class B type 1 (SR-B1), inhibiting glycolysis and lipid uptake while promoting cholesterol efflux. Here, SLC37A2 is linked to inflammatory bowel disease.